A single-nucleotide polymorphism of the beta 2-adrenergic receptor gene can predict pathological complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer

Yueyao Du,* Tingting Yan,* Liheng Zhou, Wenjin Yin, Jinsong Lu Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China *These authors contributed equally to this work Background: Germline genetic polymorphisms in certain genes are assoc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Du Y, Yan T, Zhou L, Yin W, Lu J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	beta 2-adrenergic receptor gene locally advanced breast cancer neoadjuvant chemotherapy pathological complete response polymorphism Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/79bfcd65f25749c4b1f24335f6e54924
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:79bfcd65f25749c4b1f24335f6e54924
record_format	dspace
spelling	oai:doaj.org-article:79bfcd65f25749c4b1f24335f6e549242021-12-02T03:51:21ZA single-nucleotide polymorphism of the beta 2-adrenergic receptor gene can predict pathological complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer1179-1314https://doaj.org/article/79bfcd65f25749c4b1f24335f6e549242018-11-01T00:00:00Zhttps://www.dovepress.com/a-single-nucleotide-polymorphism-of-the-beta-2-adrenergic-receptor-gen-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Yueyao Du,* Tingting Yan,* Liheng Zhou, Wenjin Yin, Jinsong Lu Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China *These authors contributed equally to this work Background: Germline genetic polymorphisms in certain genes are associated with the response to anthracycline- and taxane-based neoadjuvant chemotherapy in breast cancer (BC). This translational study aims to evaluate the potential role of rs1042713 in the beta 2-adrenergic receptor (ADRB2) gene in predicting pathological complete responses (pCRs) to taxane- and platinum-based neoadjuvant chemotherapy in locally advanced breast cancer (LABC).Materials and methods: The distribution frequencies of rs1042713 were genotyped in LABC patients who received taxane- and platinum-based neoadjuvant chemotherapy. Associations between tumor-relevant biomarkers, genotypes and pCRs were evaluated using Student’s t-test for continuous variables and Chi-square or Fisher’s exact test for categorical variables. For univariate analysis, the relationship between the rs1042713 polymorphism and pCR was analyzed by Chi-square or Fisher’s exact test. The modified ORs with their 95% CIs were calculated by a multivariate logistic regression analysis to explore the association between genotype and pCR.Results: There was a significant correlation of the rs1042713 genotype with estrogen receptor (ER) status (P=0.008). Significant differences were detected in the rs1042713 genotypes of pCR and non-pCR patients (P=0.046). The pCR rate was 18.2% in patients with ADRB2 rs1042713 AA genotypes and 38.7% in AG+GG genotypes. Women carrying the AG+GG (OR=2.91, 95% CI: 1.02–8.29, P=0.046) genotype had a higher pCR rate than those with the AA genotype.Conclusion: rs1042713, which is located in the ADRB2 gene, could predict pCR to taxane- and platinum-based neoadjuvant chemotherapy in LABC. This finding suggests that rs1042713 could play a potential role as a predictive marker in clinical settings. Keywords: beta 2-adrenergic receptor gene, locally advanced breast cancer, neoadjuvant chemotherapy, pathological complete response, polymorphism Du YYan TZhou LYin WLu JDove Medical Pressarticlebeta 2-adrenergic receptor genelocally advanced breast cancerneoadjuvant chemotherapypathological complete responsepolymorphismNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 10, Pp 201-206 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	beta 2-adrenergic receptor gene locally advanced breast cancer neoadjuvant chemotherapy pathological complete response polymorphism Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	beta 2-adrenergic receptor gene locally advanced breast cancer neoadjuvant chemotherapy pathological complete response polymorphism Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Du Y Yan T Zhou L Yin W Lu J A single-nucleotide polymorphism of the beta 2-adrenergic receptor gene can predict pathological complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer
description	Yueyao Du,* Tingting Yan,* Liheng Zhou, Wenjin Yin, Jinsong Lu Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China *These authors contributed equally to this work Background: Germline genetic polymorphisms in certain genes are associated with the response to anthracycline- and taxane-based neoadjuvant chemotherapy in breast cancer (BC). This translational study aims to evaluate the potential role of rs1042713 in the beta 2-adrenergic receptor (ADRB2) gene in predicting pathological complete responses (pCRs) to taxane- and platinum-based neoadjuvant chemotherapy in locally advanced breast cancer (LABC).Materials and methods: The distribution frequencies of rs1042713 were genotyped in LABC patients who received taxane- and platinum-based neoadjuvant chemotherapy. Associations between tumor-relevant biomarkers, genotypes and pCRs were evaluated using Student’s t-test for continuous variables and Chi-square or Fisher’s exact test for categorical variables. For univariate analysis, the relationship between the rs1042713 polymorphism and pCR was analyzed by Chi-square or Fisher’s exact test. The modified ORs with their 95% CIs were calculated by a multivariate logistic regression analysis to explore the association between genotype and pCR.Results: There was a significant correlation of the rs1042713 genotype with estrogen receptor (ER) status (P=0.008). Significant differences were detected in the rs1042713 genotypes of pCR and non-pCR patients (P=0.046). The pCR rate was 18.2% in patients with ADRB2 rs1042713 AA genotypes and 38.7% in AG+GG genotypes. Women carrying the AG+GG (OR=2.91, 95% CI: 1.02–8.29, P=0.046) genotype had a higher pCR rate than those with the AA genotype.Conclusion: rs1042713, which is located in the ADRB2 gene, could predict pCR to taxane- and platinum-based neoadjuvant chemotherapy in LABC. This finding suggests that rs1042713 could play a potential role as a predictive marker in clinical settings. Keywords: beta 2-adrenergic receptor gene, locally advanced breast cancer, neoadjuvant chemotherapy, pathological complete response, polymorphism
format	article
author	Du Y Yan T Zhou L Yin W Lu J
author_facet	Du Y Yan T Zhou L Yin W Lu J
author_sort	Du Y
title	A single-nucleotide polymorphism of the beta 2-adrenergic receptor gene can predict pathological complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer
title_short	A single-nucleotide polymorphism of the beta 2-adrenergic receptor gene can predict pathological complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer
title_full	A single-nucleotide polymorphism of the beta 2-adrenergic receptor gene can predict pathological complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer
title_fullStr	A single-nucleotide polymorphism of the beta 2-adrenergic receptor gene can predict pathological complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer
title_full_unstemmed	A single-nucleotide polymorphism of the beta 2-adrenergic receptor gene can predict pathological complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer
title_sort	single-nucleotide polymorphism of the beta 2-adrenergic receptor gene can predict pathological complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/79bfcd65f25749c4b1f24335f6e54924
work_keys_str_mv	AT duy asinglenucleotidepolymorphismofthebeta2adrenergicreceptorgenecanpredictpathologicalcompleteresponsetotaxaneandplatinumbasedneoadjuvantchemotherapyinbreastcancer AT yant asinglenucleotidepolymorphismofthebeta2adrenergicreceptorgenecanpredictpathologicalcompleteresponsetotaxaneandplatinumbasedneoadjuvantchemotherapyinbreastcancer AT zhoul asinglenucleotidepolymorphismofthebeta2adrenergicreceptorgenecanpredictpathologicalcompleteresponsetotaxaneandplatinumbasedneoadjuvantchemotherapyinbreastcancer AT yinw asinglenucleotidepolymorphismofthebeta2adrenergicreceptorgenecanpredictpathologicalcompleteresponsetotaxaneandplatinumbasedneoadjuvantchemotherapyinbreastcancer AT luj asinglenucleotidepolymorphismofthebeta2adrenergicreceptorgenecanpredictpathologicalcompleteresponsetotaxaneandplatinumbasedneoadjuvantchemotherapyinbreastcancer AT duy singlenucleotidepolymorphismofthebeta2adrenergicreceptorgenecanpredictpathologicalcompleteresponsetotaxaneandplatinumbasedneoadjuvantchemotherapyinbreastcancer AT yant singlenucleotidepolymorphismofthebeta2adrenergicreceptorgenecanpredictpathologicalcompleteresponsetotaxaneandplatinumbasedneoadjuvantchemotherapyinbreastcancer AT zhoul singlenucleotidepolymorphismofthebeta2adrenergicreceptorgenecanpredictpathologicalcompleteresponsetotaxaneandplatinumbasedneoadjuvantchemotherapyinbreastcancer AT yinw singlenucleotidepolymorphismofthebeta2adrenergicreceptorgenecanpredictpathologicalcompleteresponsetotaxaneandplatinumbasedneoadjuvantchemotherapyinbreastcancer AT luj singlenucleotidepolymorphismofthebeta2adrenergicreceptorgenecanpredictpathologicalcompleteresponsetotaxaneandplatinumbasedneoadjuvantchemotherapyinbreastcancer
_version_	1718401604005134336

A single-nucleotide polymorphism of the beta 2-adrenergic receptor gene can predict pathological complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer

Ejemplares similares